Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead product candidates include VB-111, a gene-based biologic, which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer, as well as VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.
http://www.priceseries.com/trade/VBLT-Vascular-Biogenics-Ltd-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018060520180621.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments